Clinical trials: sponsored by Bristol-Myers Squibb
Hepatitis B Infection
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.
- Trial name
- NCT00371150
- Testing
- Entecavir
- Where
- 27 sites in United States, Brazil and 3 more
- Volunteers
- 131 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of…
- Trial name
- NCT00101660
- Testing
- Dasatinib
- Where
- 85 sites in United States, Australia and 20 more
- Volunteers
- 387 people
- Sponsor
- Bristol-Myers Squibb
Scleroderma
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
- Trial name
- NCT00764309
- Testing
- dasatinib
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for…
- Trial name
- NCT00124982
- Testing
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Where
- 148 sites in United States, Belgium and 8 more
- Volunteers
- 1,286 people
- Sponsor
- Bristol-Myers Squibb
HIV
Phase IIB Pilot of Atazanavir + Raltegravir
The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).
- Trial name
- SPARTAN (NCT00768989)
- Testing
- Atazanavir, Raltegravir, Ritonavir
- Where
- 16 sites in United States, Argentina and 1 more
- Volunteers
- 167 people
- Sponsor
- Bristol-Myers Squibb
Active Rheumatoid Arthritis
A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone…
- Trial name
- NCT00420199
- Testing
- Abatacept
- Where
- 10 sites in Belgium, Germany and 4 more
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis (RA)
Methotrexate - Inadequate Response Device Sub-Study
The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.
- Trial name
- MTX-IR (NCT01173120)
- Testing
- Abatacept combination product (ACP)
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not…
- Trial name
- NCT00048568
- Testing
- Abatacept, Methotrexate
- Where
- 48 sites in United States
- Volunteers
- 1,250 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.
- Trial name
- NCT00048932
- Testing
- Double-blind Abatacept, Open-label Abatacept
- Where
- 44 sites in United States
- Volunteers
- 1,795 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who…
- Trial name
- NCT00048581
- Testing
- Abatacept
- Where
- 42 sites in United States
- Volunteers
- 738 people
- Sponsor
- Bristol-Myers Squibb
HIV Infection
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.
- Trial name
- NCT00326716
- Testing
- Atazanavir + Ritonavir + Combivir
- Where
- 6 sites in United States, Puerto Rico and 1 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Metastases
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV…
- Trial name
- NCT00094653
- Testing
- MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
- Where
- 209 sites in United States, Argentina and 11 more
- Volunteers
- 1,783 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease…
- Trial name
- NCT00989235
- Testing
- Abatacept
- Volunteers
- 108 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV.
- Trial name
- NCT00272779
- Testing
- ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet
- Where
- 79 sites in United States, Argentina and 27 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.
- Trial name
- NCT00978731
- Testing
- Dasatinib
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Metastasis
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
- Trial name
- NCT00371345
- Testing
- Dasatinib, Dasatinib 100 mg
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
The purpose of this clinical research study is to learn if BMS-354825 will have activity, defined by hematologic response, in subjects who have accelerated phase chronic myeloid leukemia (CML) who are resistant to or intolerant…
- Trial name
- NCT00101647
- Testing
- Dasatinib
- Where
- 70 sites in United States, Argentina and 21 more
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Metastasis
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.
- Trial name
- NCT00371254
- Testing
- Dasatinib
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with…
- Trial name
- NCT00035932
- Testing
- Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
- Where
- 29 sites in United States
- Volunteers
- 571 people
- Sponsor
- Bristol-Myers Squibb
Myeloid Leukemia, Chronic
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice…
- Trial name
- NCT00482703
- Testing
- Dasatinib
- Where
- 9 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb